Griffin Asset Management Inc. grew its stake in Merck & Co., Inc. (NYSE:MRK – Get Rating) by 20.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 123,722 shares of the company’s stock after purchasing an additional 21,390 shares during the quarter. Merck & Co., Inc. makes up approximately 1.3% of Griffin Asset Management Inc.’s investment portfolio, making the stock its 16th largest holding. Griffin Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $10,151,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Financial Avengers Inc. increased its position in Merck & Co., Inc. by 115.8% during the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock worth $25,000 after acquiring an additional 176 shares during the period. Front Row Advisors LLC grew its stake in Merck & Co., Inc. by 89.4% during the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after buying an additional 160 shares in the last quarter. Moisand Fitzgerald Tamayo LLC grew its stake in Merck & Co., Inc. by 78.0% during the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock worth $27,000 after buying an additional 156 shares in the last quarter. Okabena Investment Services Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $27,000. Finally, Western Pacific Wealth Management LP acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $29,000. 72.88% of the stock is currently owned by institutional investors.
MRK has been the subject of a number of research reports. Morgan Stanley dropped their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. StockNews.com initiated coverage on shares of Merck & Co., Inc. in a report on Thursday, March 31st. They issued a “strong-buy” rating for the company. SVB Leerink reiterated an “outperform” rating and issued a $102.00 price objective on shares of Merck & Co., Inc. in a report on Monday, June 6th. Barclays boosted their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Finally, Mizuho initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, April 1st. They set a “buy” rating and a $100.00 target price for the company. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $91.60.
Merck & Co., Inc. (NYSE:MRK – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.81 by $0.33. The business had revenue of $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 47.86%. Merck & Co., Inc.’s revenue was up 31.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 7.32 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 8th. Investors of record on Wednesday, June 15th will be given a $0.69 dividend. The ex-dividend date is Tuesday, June 14th. This represents a $2.76 annualized dividend and a yield of 3.10%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.37%.
Merck & Co., Inc. Company Profile (Get Rating)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.